Financial Information

Immatics has a solid financial basis, with leading international life science investors supporting its business.

Through its series A financing round in 2004/2005, Immatics raised more than €14 million from top tier venture capital firms.

In February 2007, in addition to the existing consortium, Dietmar Hopp as the new lead investor together with new co-investors, committed additional €40 million to support the success story of Immatics.

A series C financing round of €54 million was raised in September 2010 with approximately half of the investment coming from new investors MIG AG and AT Impf GmbH.

In October 2013 a series D financing round of up to €34 million was closed with all of the funding coming from existing investors, including dievini Hopp Biotech holding, Wellington Partners, MIG-advised funds and AT Impf GmbH.

In addition to private and institutional funding, Immatics and Immatics US, Inc. have been granted more than $30 million of funding from the German State of Baden-Württemberg, the German Federal Ministry of Education and Research (BMBF), the European Commission (EU FP7 program) and the Cancer Prevention and Research Institute of Texas (CPRIT).


Please find the largest investors in Immatics listed below.

AT Impf GmbH

Dievini Hopp BioTech Holding GmbH & Co.KG

EMBL Ventures

Grazia Equity

KfW Anstalt des öffentlichen Rechts

L-Bank (L-EA)

MIG Fonds

Merifin Capital

National Technology Enterprises Company 

Renaissance PME fondation suisse d’investissement

Wellington Partners